Background and aims
Among cardiovascular ris
k factor, people with Down s
yndrome have a lower plasma homoc
ysteine level. In a previous stud
y, we have shown that DYRK1A (dual-specificit
y t
yrosine-(Y)-phosphor
ylation regulated
kinase 1a), a serine/threonine
kinase found on human chromosome 21, is implicated on homoc
ysteine metabolism regulation. Indeed, mice that overexpress in liver this
kinase have a lower plasma homoc
ysteine level concomitant with an increased hepatic S-adenos
yhomoc
ysteine h
ydrolase (SAHH) activit
y, which depends on the activation of NAD(P)H:quinone oxidoreductase-1 (NQO1). Since NQO1 gene transcription is under the control of NRF2 and AhR, the aim of the present stud
y was to anal
yze the effect of DYRK1A overexpression in mice onto NRF2 and AhR signaling pathwa
ys.
Methods
Effects of DYRK1A overexpression were examined in mice overexpressing Dyrk1a treated with an inhibitor, harmine, by real-time quantitative reverse-transcription polymerase reaction and western blotting.
Results
We found that overexpression of DYRK1A increases the nuclear NRF2 quantity, concomitant with the activation of ERK1/2. We also show that the overexpression of Dyrk1a has no effect on PI3K/AKT activation, and AhR signaling pathway in liver of mice.
Conclusions
Our results reveal a link between DYRK1A and NRF2 signaling pathway.